Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Illumina Advises Stockholders To Take No Action In Response To Roche's New Offer

RELATED NEWS
Trade ILMN now with 
3/29/2012 2:55 AM ET

Illumina, Inc. (ILMN: Quote) suggested that its stockholders take no action at this time in response to announcement by Roche Holding AG (RHHBY.PK) that it is now offering to acquire Illumina for $51.00 per share in cash.

Earlier, on February 7, 2012, Illumina's Board of Directors rejected Roche's $44.50 per share cash tender offer and recommended that stockholders not tender their shares.

Illumina stated that its Board of Directors will thoroughly review Roche's revised proposal and make a recommendation to stockholders regarding the proposal in due course.

Click here to receive FREE breaking news email alerts for Illumina Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Intel Corp. said Tuesday after the markets closed that its first quarter profit fell 5% from last year, hurt mainly by higher income tax expenses even as revenue grew slightly. The company's quarterly earnings per share came in above analysts' expectations, but its quarterly revenue fell shy of analysts' forecast. With traders digesting a mixed batch of catalysts, stocks saw considerable volatility over the course of the trading day on Tuesday before closing mostly higher. The gains on the day extended the recovery off the two-month lows set last Friday. The major averages showed a notable rebound in afternoon trading to end the day in positive territory. U.S. President Barack Obama and his Russian counterpart Vladimir Putin spoke regarding the ongoing crisis in Ukraine for the first time in over two weeks on Monday, although the two leaders remain far apart on the cause of escalating tensions.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.